A Phase 1 interventional study of ONO-4578 and ONO-4538 in Non-small Cell Lung Cancer, sponsored by Ono Pharmaceutical Co., Ltd.. Completed at 13 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.
Sponsored by Ono Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 452 studies in Carcinoma, Non-Small-Cell Lung with a site in Japan — 96 open to participants now, 215 under way, 102 of them phase 3. Carcinoma, Non-Small-Cell Lung · Japan.
Among the 452 studies in Carcinoma, Non-Small-Cell Lung with a site in Japan, this one is the 355th largest by enrollment of the 418 interventional ones that give a count, is one of 39 that started in 2021, is one of 104 in phase 1, and was the 382nd registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →96 of the 452 studies in Carcinoma, Non-Small-Cell Lung with a site in Japan are open now. Recruiting first, the newest first:
Daiichi Sankyo · Sites in Japan, United States, Argentina and 10 more countries
Ages 18+
Hoffmann-La Roche · Sites in Japan, United States, Argentina and 16 more countries
Ages 18+
Bristol-Myers Squibb · Sites in Japan, United States, Argentina and 13 more countries
Ages 18+
Novartis Pharmaceuticals · Sites in Japan, Australia
Ages 18+
Astellas Pharma Global Development, Inc. · Sites in Japan, United States, China
Ages 18+
A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →
Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
452 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 160 · Phase 2 139 · Phase 3 180 · Phase 4 5
First in 1995; this study’s year is marked. 39 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 42 is below the median of 62 across 6,024 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 284 across the 418 interventional studies, 500 across the 27 observational. Of the 226 that completed or were terminated, 141 (62%) have results posted.
This tab as a report to print or save as PDF → With an account.
421 of 452 have an industry lead sponsor. The 10 most frequent:
This study is registered under Ono Pharmaceutical Co., Ltd., one of the names counted as Ono Pharmaceutical Co. Ltd. Under that name alone:
Ono Pharmaceutical Co., Ltd. is the lead sponsor of 49 studies on the registry; 18 are open to participants now.
Ono Pharmaceutical Co. Ltd has 9 studies filed under Carcinoma, Non-Small-Cell Lung — fewer than ten, so there is no comparison to draw.
42 of the studies in Carcinoma, Non-Small-Cell Lung with a site in Japan that are under way reach primary completion within a year, 15 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03815643Phase 3EMD Serono Research & Development Institute, Inc.Avelumab Program Rollover Study | 2026-11-24 |
| NCT05221840Phase 3AstraZenecaA Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer | 2027-01-08 |
| NCT06417814Phase 3AstraZenecaA Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | 2027-01-11 |
| NCT05609968Phase 3Merck Sharp & Dohme LLCStudy of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46) | 2027-01-12 |
| NCT05170204Phase 3Hoffmann-La RocheA Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC) | 2027-01-19 |
Add all 42 to your calendar (.ics) → With an account.
Among the 452 studies in Carcinoma, Non-Small-Cell Lung with a site in Japan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is PhaseⅠstudy to evaluate the tolerability and safety of ONO-4578 and ONO-4538 in combination with standard-of-care docetaxel and ramucirumab as second-line therapy in patients with advanced or recurrent NSCLC who were refractory to a combination therapy containing an anti-PD-(L)1 antibody and a platinum-based drug
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: ONO-4578 · Drug: ONO-4538 · Drug: Docetaxel · Drug: Ramucirumab
Specified dose on specified days
Specified dose on specified days
Also known as: Nivolumab
Specified dose on specified days
Also known as: Taxotere
Specified dose on specified days
Also known as: Cyramza
Dose-limiting toxicities(DLT)
Time frame: 21 days
Adverse event(AE)
Time frame: Up to 28 days after the last dose
Pharmacokinetics(Plasma concentration of ONO-4578)
Time frame: Up to 28 days after the last dose
Pharmacokinetics(serum concentration of ONO-4538)
Time frame: Up to 28 days after the last dose
Overall response rate (ORR)
Time frame: Up to 2 years
Disease control rate (DCR)
Time frame: Up to 2 years
Overall survival (OS)
Time frame: Up to 2 years
Progression-free survival (PFS)
Time frame: Up to 2 years
Duration of response (DOR)
Time frame: Up to 2 years
Time to response (TTR)
Time frame: Up to 2 years
Best overall response (BOR)
Time frame: Up to 2 years
Percentage of change in the sum of tumor diameters of target lesions
Time frame: Up to 2 years
Maximum percentage of change in the sum of tumor diameters of target lesions
Time frame: Up to 2 years
Changes in tumor markers(CYFRA,CEA,SLX)
Time frame: Up to 2 years
Plan to share: No
No publications or documents are linked to this record.
Ran from Jun 2021 to primary completion in Oct 2025, 52 months.
Of 474 industry-sponsored phase 1 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 66. This study's 52 months is close to that.
Counting every sponsor, half of 700 studies reached it within 50 months; a quarter within 31 and three quarters within 70.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 20, 2026: primary completion Sep 2026 → Oct 2025 and completion Dec 2026 → Oct 2025.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: BMS-986310
Carcinoma, Non-Small-Cell Lung →
Ono Pharmaceutical Co., Ltd. →